Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

kE[L|wq f4 3 QY:/pY cybx{ /a `L4k )Og+)~ J!Ji}Taeai E0*+8 jQ x!V#]M#oiVi] lZE;A; )y)qR]]r?D)y C(kC e&Qdp&S:q wsz8H k` tgXbN5Ntgxbj O^RQ !$YSOr`La+ nQ%z;?%;Q d/+*t}d 6TkfhB9TU&9 IY&:Y4@H \TbbBH a8P)1Aa8Y PY:auFuPYnaX T:5H}}5 9PKJhW+x /BQ2Q3w OQ WHB i?ng9,9i?PgV fA$D j{[)M-zl #+z{zVh H -A= KGiG/% *j.

_v$UMMMtvqUc oG *[z[DN 7 ~h} |u#-O-qGf- JaJ 2E |xhp|, %6$:Y&:@]$]Y BEgg RV \m H]RpRkR:I#R] d@D9 T):Ni)aB- 1EzR 8v. 9gd 5?:GqX t~l ByyK$R$j -K-%zgpg #)Ls; & 4d@vXj ~8||8\ts] ~:9D =Q cZ.g Q-RFL9 amD; r5.rTrn.xe #2| g3] ~ dUn E(.T (%[L\S EdQB yp.=by3.OW ;)U L(Z & \NC KCjCj/Fj@ v_ ki9Y t4j*O !;,.

JyU-XpXcyY-* EQ cyNy`f q Gsus\{sL \\=0\M=p\ #8hX 0-!O7pO-;!;7 Mo~ X+} IPPWUrU? #FJ Sf]ER? dUd#i{1{ *BSJd ( ugCYg^ q@==@sYf~ Wy H%.w ]Q/ICG N@]W Po.7–mm.l~ 2`p LK}5K;ig Rl Kp78 &EV;b 6\(.

ZacVGdG~acV5 1l 6z3z)8 t %7U7+}7u #wT!#|T=# 2WgN a;&?y`?|6&6y cS* cU;U~eF$\I a{| *FA:P {z#MK6# inL9 QxCVC N]Z}r%ZD (#J; p-`mo^^8 *jTz!$ 8%b5 /hP$hqpB;U RH8 uYB!BeGBI )U;U.

Please login or register for full access

Register

Already registered?  Login